Yahoo Finance • yesterday
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils Approval marks the first new treatment approach for COPD in more than a decade in Japan and t... Full story
Yahoo Finance • yesterday
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophilsApproval... Full story
Yahoo Finance • yesterday
Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO Cette approbation fait suite à celle obtenue récemment dans l’Union européenne, en Chine et aux États-Unis et repose sur les résultats pivot... Full story
Yahoo Finance • 4 days ago
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. fin... Full story
Yahoo Finance • 4 days ago
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best extremely profi... Full story
Yahoo Finance • 4 days ago
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Investors who purchased shares of Regener... Full story
Yahoo Finance • 17 days ago
TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Matteo Paz,18, of Pasadena, CA, won the top award of $250,000 in the 2... Full story
Yahoo Finance • 19 days ago
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both... Full story
Yahoo Finance • 19 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDA... Full story
Yahoo Finance • 19 days ago
NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit s... Full story
Yahoo Finance • 19 days ago
LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story
Yahoo Finance • 21 days ago
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly reduced oral corticosteroid and rescue... Full story
Yahoo Finance • 21 days ago
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease... Full story
Yahoo Finance • 21 days ago
Présentation de dernière heure de données pivots positives sur le Dupixent dans le traitement de la pemphigoïde bulleuse à l’AAD Cinq fois plus d’adultes traités par Dupixent présentaient une rémission soutenue à la semaine 36, comparativ... Full story
Yahoo Finance • 22 days ago
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both... Full story
Yahoo Finance • 22 days ago
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit s... Full story
Yahoo Finance • 22 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in... Full story
Yahoo Finance • 23 days ago
SAN FRANCISCO, March 06, 2025 (GLOBE NEWSWIRE) -- Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for... Full story
Yahoo Finance • 23 days ago
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are... Full story
Yahoo Finance • 24 days ago
LOS ANGELES, March 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or other... Full story